InNexus Biotechnology Inc. Announces Discovery of Novel Protein for AMD Eye Disorder - Will Bypass Needles with Topical Application
CHANDLER, Ariz.--(BUSINESS WIRE)--InNexus Biotechnology Inc. (TSX:IXS.V)(www.ixsbio.com), a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced that it has developed IXS312(VEGF), an antibody fragment with activity against the growth factor VEGF for planned use in ocular treatments.